Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Substantial late mortality risk persists after childhood BMT

Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

Key clinical point: Individuals undergoing allogeneic blood or marrow transplantation (BMT) in childhood require careful follow-up for many years because of a persistent elevated risk of premature death.

Major finding: Risk of premature death was increased 14.4-fold, compared with the general population (95% confidence interval, 12.8-16.1).

Study details: A retrospective cohort study including 1,388 individuals living 2 years or more after allogeneic BMT performed in childhood.

Disclosures: The study was supported in part by grants from the National Cancer Institute, the Leukemia Lymphoma Society, and the Swedish Childhood Cancer Foundation. Dr. Holmqvist and her coauthors reported no conflicts of interest.

Read article here.

Citation:

Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.

This Week's Must Reads

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.

New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.